Cyclodextrins: Their future in drug formulation and delivery

Pharmaceutical Research

Volumn 14, Issue 5, 1997, Pages 556-567

  Stella, Valentino J ^a   Rajewski, Roger A ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Cyclodextrins; Drug delivery; Drug formulation; Pharmacokinetics

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 2,6 O DIMETHYL BETA CYCLODEXTRIN; ACETAZOLAMIDE; ALPHA CYCLODEXTRIN; ANESTHETIC AGENT; ATOVAQUONE; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; CARBAMAZEPINE; CEFOTIAM HEXETIL; CINNARIZINE; CYCLODEXTRIN DERIVATIVE; CYCLOSPORIN A; DILTIAZEM; FLURBIPROFEN; GAMMA CYCLODEXTRIN; GLYCEROL NITRATE; ITRACONAZOLE; MOLSIDOMINE; NAPROXEN; OCTREOTIDE; PILOCARPINE; PIROXICAM BETA CYCLODEXTRIN; PREDNISOLONE; PRODRUG; PROPOFOL; PROSTAGLANDIN E1; PROSTAVASIN; THIOPENTAL; TIAPROFENIC ACID; UNINDEXED DRUG;

COMPLEX FORMATION; DISSOLUTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INFORMATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; ENCAPSULATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAOCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; POTASSIUM EXCRETION; PRIORITY JOURNAL; RABBIT; RAT; RECTAL DRUG ADMINISTRATION; REVIEW; SOLUBILIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; TOPICAL DRUG ADMINISTRATION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DRUG CARRIERS; DRUG COMPOUNDING; HUMANS; LEGISLATION, DRUG;

EID: 8244248457     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012136608249     Document Type: Review

References (69)

1. T. Loftsson and M. Brewster. Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization. J. Pharm. Sci. 85:1017-1025 (1996).
2. T. Irie and K. Uekama. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86:147-162 (1997).
3. K. Frömming and J. Szejtli. Cyclodextrins in Pharmacy; Kluwer Acad. Publ., Dordrecht, 1994.
4. J. Szejtli. Cyclodextrin Technology; J.E.D. Davies (series ed.), Kluwer Acad.; Dordrecht, 1988.
5. Cyclodextrins and their Industrial Uses, D. Duchêne (ed.), Editions de Santé, Paris, 1987.
6. T. Loftsson. Effects of cyclodextrins on the chemical stability of drugs in aqueous solutions. Drug Stab. 1:22-33 (1995).
7. H. Van Doorne. Interactions between cyclodextrins and ophthalmic drugs. Eur. J. Pharm. Biopharm. 39:133-139 (1993).
8. R. A. Rajewski and V. J. Stella. Pharmaceutical applications of cyclodextrins. II. In vivo drug delivery. J. Pharm. Sci. 85:1142-1169 (1996).
9. D. O. Thompson. Cyclodextrins - enabling excipients: Their present and future use in pharmaceuticals. In S. Bruck (ed.), Critical Reviews in Drug Carrier Systems, CRC Press, (1997), in press.
10. K. Uekama, F. Hirayama, and T. Irie. Application of cyclodextrins in pharmaceutical preparations. Drug Targeting Delivery 3:411-456 (1994).
11. A. Hersey, B. H. Robinson, and H. C. Kelly. Mechanisms of inclusion-compound formation for binding of organic dyes, ions and surfactants to alpha-cyclodextrin studied by kinetic methods based on competition experiments. J. Chem . Soc. Faraday Trans. 1 82:1271-1287 (1986).
12. F. Cramer, W. Saenger, and H. C. Spatz. Inclusion compounds. XIX. The formation of inclusion compounds of α-cyclodextrin in aqueous solutions. Thermodynamics and kinetics. J. Am. Chem. Soc. 89:14-20 (1967).
13. H. W. Frijlink, E. J. F. Franssen, A. C. Eissens, R. Oosting, C. F. Lerk, and D. K. F. Meijer. The effects of cyclodextrins on the disposition of intravenously injected drugs in the rat. Pharm. Res. 8:380-384 (1991).
14. D. W. Frank, J. E. Gray, and R. N. Weaver, Cyclodextrin nephrosis in the rat. Am. J. Pathol. 83:367-382 (1976).
15. R. A. Rajewski, G. Traiger, J. Bresnahan, P Jaberaboansari, V. J. Stella, and D. O. Thompson. Preliminary safety evaluation of parenterally administered sulfoalkyl ether β-cyclodextrin derivatives. J. Pharm. Sci. 84:927-932 (1995).
16. G. Antlsperger and G. Schmid. Toxicological Comparison of Cyclodextrins. In Proceedings of the 8th International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1996, pp. 149-155.
17. B. W. Müller and U. Brauns. Hydroxypropyl-β-cyclodextrin derivatives: influence of average degree of substitution on complexing ability and surface activity. J. Pharm. Sci. 75:571-572 (1986).
18. C. T. Rao, J. Pitha, B. Lindberg, and J. Lindberg. Distribution of substituents in O-(2-hydroxypropyl) derivatives of cyclomalto-oligosaccharides (cyclodextrins): influence of increasing substitution, of the base used in the preparation, and of macrocyclic size. Carbohydr. Res. 223:99-107 (1992).
19. J. Pitha. Amorphous water-soluble derivatives of cyclodextrins: from test tube to patient. J. Controlled Release 6:309-313 (1987).
20. V. Zia, R. Rajewski, E. R. Bornancini, E. A. Luna, and V. J. Stella. Effect of alkyl chain length and degree of substitution on the complexation of sulfoalkyl ether β-cyclodextrins with steroids. J. Pharm. Sci. 86:220-224 (1997).
21. W. Löscher, D. Hoenack, A. Richter, H. Schulz, M. Schuerer, R. Duesing, and M. E. Brewster. New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl-β-cyclodextrin: Tolerability and pharmacokinetics after intravenous injection in comparison to a glycofurol-based formulation. Epilepsia (N. Y.). 36:255-261 (1995).
22. K. Arimori, R. Iwaoku, M. Nakano, Y. Uemura, M. Otagiri, and K. Uekama. Improvement of some pharmaceutical properties of thiopental by γ-cyclodextrin complexation. Yakugaku Zasshi 103:553-558 (1983).
23. H. Viernstein, C. Stumpf, P. Spiegl, and S. Reiter. Preparation and central action of propofol/hydroxypropyl-β-cyclodextrin complexes in rabbits. Arzneim-Forsch. 43:818-821 (1993).
24. H. Viernstein, C. Stumpf, and S. Reiter. Intravenous anesthesia with isoflurane in the rabbit. Pharm. Pharmacol. Lett. 3:165-168 (1994).
25. M. E. Brewster, W. R. Anderson, T. Loftsson, M. Huang, N. Bodor, and E. Pop. Preparation, characterization and anesthetic properties of 2-hydroxypropyl-β-cyclodextrin complexes of pregnanolone and pregnenolone in rat and mouse. J. Pharm. Sci. 84:1154-1159 (1995).
26. A. Doenicke, M. F. Roizen, A.E. Nebauer, A. Kugler, R. Hoernecke, and H. Beger-Hintzen. A comparison of two formulations for etomidate, 2-hydroxypropyl-β-cyclodextrin (HPCD) and propylene glycol. Anesth. Analg. (N. Y.) 79:933-939 (1994).
27. K. Arimori and K. Uekama. Effects of β- and γ-cyclodextrins on the pharmacokinetic behavior of prednisolone after intravenous and intramuscular administrations to rabbits. J. Pharmacobio-Dyn. 10:390-395 (1987).
28. K. Dietzel, K. S. Estes, M. E. Brewster, N. S. Bodor, and H. Derendorf. The use of 2-hydroxypropyl-β-cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs. Int. J. Pharm. 59:225-230 (1990).
29. V. J. Stella, H. K. Lee, and D. O. Thompson. The effect of SBE4-β-CD on i.v. methylprednisolone pharmacokinetics in rats: Comparison to a co-solvent solution and two water-soluble prodrugs. Int. J. Pharm. 120:189-195 (1995).
30. T. Järvinen, K. Järvinen, N. Schwarting, and V. J. Stella, β-Cyclodextrin derivatives, SBE4-CD and HP-CD, increase the oral bioavailability of cinnarizine in beagle dogs. J. Pharm. Sci. 84:295-299 (1995).
31. V. J. Stella, H. K. Lee, and D. O. Thompson. The effect of SBE4-β-CD on i.m. prednisolone pharmacokinetics and tissue damage in rabbits: Comparison to a co-solvent solution and a water-soluble prodrug. Int. J. Pharm. 120:197-204 (1995).
32. R. Panini, M. A. Vandelli, F. Forni, J. M. Pradelli, and G. Salvioli. Improvement of ursodeoxycholic acid bioavailability by 2-hydroxypropyl-β-cyclodextrin complexation in healthy volunteers. Pharmacol. Res. 31:205-209 (1995).
33. S. D. Studenberg, A. K. Roy, and J. L. Woolley. Comparative pharmacokinetic and bioavailability studies of atovaquone in dogs. 1. Cyclodextrin complexation. Pharm. Res. 13:S-457 (1996).
34. B. Haeberlin, T. Gengenbacher, A. Meinzer, and G. Fricker. Cyclodextrins - useful excipients for oral peptide administration? Int. J. Pharm. 137:103-110 (1996).
35. K. Uekama, T. Horikawa, Y. Horiuchi, and F. Hirayama. In vitro and in vivo evaluation of delayed-release behavior of diltiazem from its O-carboxymethyl-O-ethyl β-cyclodextrin complex. J. Controlled Release 25:99-106 (1993).
36. T. Horikawa, F. Hirayama, and K. Uekama. In vivo and in vitro correlation for delayed-release behavior of a molsidomine/O-carboxymethyl-O-ethyl-β-cyclodextrin complex in gastric aciditycontrolled dogs. J. Pharm. Pharmacol. 47:124-127 (1995).
37. T. Jansen, B. Xhonneux, J. Mesens, and M. Borgers. β-Cyclodextrins as vehicles in eye-drop formulations: an evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxic. Res. 7:459-468 (1990).
38. K. Järvinen, T. Järvinen, D. O. Thompson, and V. J. Stella. The effect of a modified β-cyclodextrin, SBE4-β-CD, on the aqueous stability and ocular absorption of pilocarpine. Curr. Eye Res. 13:897-905 (1994).
39. K. A. Freedman, J. W. Klein, and C. E. Crosson, β-Cyclodextrins enhance availability of pilocarpine. Curr. Eye Res. 12:641-647 (1993).
40. O. Reer, T. K. Bock, and B. W. Müller. In vitro corneal permeability of diclofenac sodium in formulations containing cyclodextrins compared to the commercial product Voltaren Ophtha. J. Pharm. Sci. 83:1345-1349 (1994).
41. T. Takano, C. Kobayashi, R. M. Alba, and A. Kanai. The immunosuppresive effects of 0.025% cyclosporin eye drops in α-cyclodextrin on rabbit corneal allografts. Nippon Ganka Gakkai Zasshi 96:834-40 (1992).
42. A. Usayapant, A. H. Karara, and M. M. Narurkar. Effect of 2-hydroxypropyl-β-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate. Pharm. Res. 8:1495-1499 (1991).
43. T. Loftsson, H. Fridriksdóttir, S. Thórisdóttir, and E. Stefánsson. The effect of hydroxypropyl methyl cellulose on the release of dexamethasone from aqueous 2-hydroxypropyl-β-cyclodextrin formulations. Int. J. Pharm. 104:181-184 (1994).
44. T. Loftsson, H. Fridriksdóttir, E. Stefánsson, S. Thórisdóttir, O. Guómundsson, and T. Sigthórsson. Topically effective ocular hypotensive acetazolamide and ethoxyzolamide formulations in rabbits. J. Pharm. Pharmacol. 46:503-504 (1994).
45. D. W. Pate, K. Järvinen, A. Urtti, P. Jarho, and T. Järvinen. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Curr. Eye Res. 14:791-797 (1995).
46. T. Järvinen, K. Järvinen, A. Urtti, D. Thompson, and V. J. Stella. Sulfobutyl ether β-cyclodextrin (SBE-β-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. J. Ocul. Pharmacol. Ther. 11:95-106 (1995).
47. P. Jarho, K. Järvinen, A. Urtti, V. J. Stella, and T. Järvinen. Modified β-cyclodextrin (SBE7-β-CD) with viscous vehicle improves the ocular delivery and tolerability of pilocarpine prodrug in rabbits. J. Pharm. Pharmacol. 48:263-269 (1996).
48. E. Marttin, J. C. Verhoef, S. G. Romeijn, and F. W. H. Merkus. Effects of absorption enhancers on rat nasal epithelium in vivo: release of marker compounds in the nasal cavity. Pharm. Res. 12:1151-1157 (1995).
49. W. A. J. Hermens, C. W. J. Beider, J. M. W. Merkus, P. M. Hooymans, J. Verhoef, and F. W. H. Merkus. Intranasal administration of estradiol in combination with progesterone to oophorectomized women: a pilot study. European J. of Obstetrics and Gynecology and Reproductive Biology 43:65-70 (1992).
50. E. Marttin, J. C. Verhoff, S. G. Romeijn, and F. W. H. M. Merkus. Cyclodextrins in nasal drug delivery: Trends and perspectives. In Proceedings of the 8th International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1996, pp. 381-386.
51. S. Hirai. Formulation studies of cefotiam hexetil hydrochloride: Effect of α-cyclodextrin as dissolution enhancer. In T. Osa (ed.), Proceedings of the 7th International Symposium on Cyclodextrins, Business Center of Academic Societies Japan, Tokyo, 1994, pp. 39-44.
52. P. Putteman, W. Caers, J. Mesens, and J. Peeters. Recent topics with regard to the use of Ecapsin™ HPB, hydroxypropyl-β-cyclodextrin, in galenical development. In The 8th International Cyclo dextrins Symposium, Programme and Abstracts, 1996, pp. 3-03.
53. G. Schmid. Preparation and application of γ-cyclodextrin. In D. Duchêne (ed.), New Trends in Cyclodextrins and Derivatives, Editions de Santé, Paris, 1991, pp. 27-54.
54. J. Serfõzõ, P. Szabo, T. Ferenczy, and A. Tôth-Jakab. Renal effects of parenterally administered methylated Cyclodextrins on rabbits. In J. Szejtli (ed.). Proceedings of the 1st International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1982, pp. 407-413.
55. S. C. Szathmary, K. U. Seiler, I. Luhmann, and H. J. Huss. Pharmacokinetic behavior and absolute bioavailability of hydroxypropyl β-cyclodextrin after increasing doses in volunteers. In D. Duchêne (ed.), Minutes of the 5th International Symposium on Cyclodextrins, Editions de Santé, Paris, 1990, pp. 535-540.
56. W. Coussement, H. Van Cauteren, J. Vandenberghe, P. Vanparys, G. Teuns, A. Lampo, and R. Marsboom. Toxicological profile of hydroxypropyl β-cyclodextrin (HP β-CD) in laboratory animals. In D. Duchêne (ed.), Minutes of the 5th International Symposium on Cyclodextrins, Editions de Santé, Paris, 1990, pp. 522-524.
57. K. U. Seiler, S. Szasthmary, H. J. Huss, R. De Coster, and W. Junge. Safety profile and intravenous tolerance of hydroxypropyl β-cyclodextrin after increasing single dose. In D. Duchêne (ed.), Minutes of the 5th International Symposium on Cyclodextrins. Editions de Santé, Paris, 1990, pp. 518-521.
58. P. Olivier, F. Verwaerde, and A. R. Hedges. Subchronic toxicity of orally administered β-cyclodextrin in rats. J. Am. Coll. Toxicol. 10:407-419 (1991).
59. A. Gerlóczy, A. Fónagy, P. Keresztes, L. Perlaky, and J. Szejtli. Absorption, distribution, excretion and metabolism of orally administered 14C-β-cyclodextrin in rat. Arzeeim,-Forsch. 35:1042-1047 (1985).
60. P. Szabo, T. Ferenczy, J. Serfõzõ, J. Szejtli, and A. Lipták. Absorption and elimination of cyclodextrin derivatives by rabbits and rats. In J. Szejtli (ed.), Proceedings of the 1st International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1982, pp. 115-122.
61. T. Irie, Y. Tsunenari, K. Uekama, and J. Pitha. Effect of bile on the intestinal absorption of α-cyclodextrin in rats. Int. J. Pharm. 43:41-44 (1988).
62. R. N. Antenucci and J. K. Palmer. Enzymic degradation of α-and β-cyclodextrins by Bacteroides of human colon. J. Agric. Food Chem. 32:1316-1321 (1984).
63. M. Suzuki and A. Sato. Nutritional significance of cyclodextrins: indigestibility and hypolipemic effect of α-cyclodextrin. J. Nutr. Sci. Vitaminol. 31:209-223 (1985).
64. M. E. Bellringer, T. G. Smith, R. Read, C. Gopinath, and P. Olivier. β-Cyclodextrin: 52-week toxicity studies in the rat and dog. Food Chem. Toxicol. 33:367-376 (1995).
65. I. Szatmári and Z. Vargay. Pharmacokinetics of dimethyl-β-cyclodextrin in rats. In D. Duchêne (ed.), Proceedings of the 4th International Symposium on Cyclodextrins, Kluwer Academic Publishers, Dordrecht, 1988, pp. 407-413.
66. J. Monbaliu, L. Van Beijsterveldt, W. Meuldermans, S. Szathmary, and J. Heykants. Disposition of hydroxypropyl β-cyclodextrin in experimental animals. In D. Duchêne (ed.), Minutes of the 5th Internationl Symposium on Cyclodextrins, Editions de Santé, Paris, 1990, pp. 514-517.
67. H. Van Cauteren, A. Lampo, L. Lammens, H. Benze, W. Coussement, and J. Vandenberghe. Monitoring pharmacodynamic effects in toxicology studies. In A. Sundwall, B. Johansson, L. Lindbom, E. Lindgren, and P. Sjöberg (eds.), Workshop on the Use of Pharmacology Studies in Drug Safety Assessment - Present Situation and Future Perspectives, (1994), pp. 101-106.
68. M. Riottot, P. Olivier, A. Huet, J. J. Caboche, M. Parquet, J. Khallou, and C. Lutton. Hypolipidemic effects of β-cyclodextrin in the hamster and the genetically hypercholesterolemic Rico rat. Lipids 28:181-188 (1988).
69. K. Shiotani, K. Uehata, T. Irie, K. Uekama, D. O. Thompson, and V. J. Stella. Differential effects of sulfate and sulfobutyl ether of β-cyclodextrin on erythrocyte membranes in vitro. Pharm. Res. 12:78-84 (1995).